BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OCULAR THERAPEUTIX\, INC readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies OCULAR THERAPEUTIX\, INC's drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06495918-4967@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Axitinib intravitreal implant (OTX-TKI): Phase 3 readout est. (NCT0
 6495918)
DESCRIPTION:Axitinib intravitreal implant (OTX-TKI)\, phase 3\, Age-Related
  Macular Degeneration.\nStudy: Study to Evaluate the Efficacy and Safety o
 f Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age
 - Related Macular Degeneration\nEstimated primary completion: 8 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/axitinib-intravit
 real-implant-otx-tki#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06495918
URL:https://assetmemo.bio/drug/axitinib-intravitreal-implant-otx-tki#upcomi
 ng-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235085-4967@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Axitinib intravitreal implant (OTX-TKI): Phase 3 readout est. (NCT0
 7235085)
DESCRIPTION:Axitinib intravitreal implant (OTX-TKI)\, phase 3.\nStudy: A St
 udy to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in P
 articipants With Non-Proliferative Diabetic Retinopathy\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/axitinib-intravitreal-implant-otx-tki#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07235085
URL:https://assetmemo.bio/drug/axitinib-intravitreal-implant-otx-tki#upcomi
 ng-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516132-4967@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300801
DTEND;VALUE=DATE:20300802
SUMMARY:Axitinib intravitreal implant (OTX-TKI): Phase 3 readout est. (NCT0
 7516132)
DESCRIPTION:Axitinib intravitreal implant (OTX-TKI)\, phase 3\, Age-Related
  Macular Degeneration.\nStudy: Study to Evaluate Long-Term Safety of Intra
 vitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Re
 lated Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-
 AMD-301 or OTX-TKI-2023-AMD-303 Study\nEstimated primary completion: 1 Aug
 ust 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/axitinib-in
 travitreal-implant-otx-tki#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07516132
URL:https://assetmemo.bio/drug/axitinib-intravitreal-implant-otx-tki#upcomi
 ng-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
